Prevention of Cyclophosphamide-Induced Immunosuppression in Mice with the Antimicrobial Peptide Sublancin

Figure 2

Effects of sublancin on the body weight in cyclophosphamide-treated mice. NC (normal control) = mice were treated with saline; MC (model control) = mice were administered with cyclophosphamide 80 mg/kg/d via i.p. injection for 3 days and gavaged with saline for 7 days; sublancin (2.0, 4.0, and 8.0) = mice were administered with cyclophosphamide 80 mg/kg/d via i.p. injection for 3 days and gavaged with sublancin at 2.0, 4.0, or 8.0 mg/kg/d for 7 days, respectively; LH (10.0) = mice were administered with cyclophosphamide 80 mg/kg/d via i.p. injection for 3 days and gavaged with levamisole hydrochloride for 7 days. Values are expressed as means ± SEM (); and compared with NC group.